Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 13 Pheochromocytoma 6 Carcinoma, Neuroendocrine 6 Somatostatinoma 5 Paraganglioma 4 Pituitary Neoplasms 3 Insulinoma 3 Glucagonoma 3 Gastrinoma 3 Zollinger-Ellison Syndrome 2 Vipoma 2 Paraganglioma, Extra-Adrenal 2 Pancreatic Neoplasms 2 Gastro-enteropancreatic neuroendocrine tumor 2 Carcinoma, Medullary 2 Carcinoma, Islet Cell 2 Carcinoid Tumor 2 Spinal Cord Neoplasms 1 Small Cell Lung Carcinoma 1 Rhabdoid Tumor 1 Prolactinoma 1 Optic Nerve Glioma 1 Oligodendroglioma 1 Non functioning pancreatic endocrine tumor 1 Neuroectodermal Tumors, Primitive 1 Neoplasms 1 Neoplasm Metastasis 1 Multiple Endocrine Neoplasia Type 2b 1 Multiple Endocrine Neoplasia Type 2a 1 Multiple Endocrine Neoplasia Type 1 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Frailty × Temozolomide × Endocrine × Clear all

NCT05554003 2024-11-18

MeTe

European Institute of Oncology

Phase 2 Recruiting

Frailty, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡